Description: Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates that have substantial preclinical, clinical and manufacturing data packages. Mereo's four product candidates have previously generated positive clinical data for Mereo's target indications or in related indications. Mereo has commenced randomized Phase 2 clinical trials for all four of the product candidates. In connection with the merger with OncoMed, Mereo added two candidates to its pipeline, Navicixizumab and Etigilimab.
Home Page: www.mereobiopharma.com
MREO Technical Analysis
One Cavendish Place
London,
W1G 0QF
United Kingdom
Phone:
44 33 3023 7300
Officers
| Name | Title |
|---|---|
| Dr. Denise Scots-Knight Ph.D. | Co-Founder, CEO & Exec. Director |
| Mr. Charles Sermon | Co-Founder, Gen. Counsel & Company Sec. |
| Dr. Alastair MacKinnon M.D., MBBS | Co-Founder and Chief of Portfolio & Pipeline Strategy |
| Dr. John P. Richard M.B.A., MBA | Co-Founder & Chief Bus. Officer |
| Ms. Christine Fox CPA | Chief Financial Officer |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer |
| Dr. Jackie Parkin | Therapy Area Head of Respiratory Endocrinology |
| Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning |
| Dr. Suba Krishnan | Sr. VP of Clinical Devel. |
| Dr. Fiona Bor | Head of Intellectual Property |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 7.7955 |
| Price-to-Book MRQ: | 1.1697 |
| Price-to-Sales TTM: | 2.8264 |
| IPO Date: | 2019-04-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 49 |